CYP2E1 and glioblastoma: Systemic knockdown of Cyp2e1 in rats and mice significantly inhibited the tumorigenesis and development of glioma, with tumor inhibition rates of 61.7% and 92.0% in knockout rats and mice, respectively, suggesting that CYP2E1 may be a potential effective therapeutic target for GBM.